[1] |
WANG Shan, XIE Bo, LIU Huimin, LI Zhihao.
Adverse event signals for celecoxib based on FAERS database
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 190-194.
|
[2] |
LI Yingfen, HAN Lei.
Analysis of 319 cases of adverse drug reaction induced by cerebroprotein hydrolysate for injection
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 195-198.
|
[3] |
LI Na, GUO Jun, GUO Wenjia, LYU Yinyin, LI Caihong, MU Xiangdong.
One case of delayed skin allergic reaction caused by asthma treated with omalizumab injection
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 211-212.
|
[4] |
GAO Xu, PENG Jin’e, LI Xingwang, ZHANG Wei.
Recent research of antiviral drugs and vaccines for Mpox
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 111-116.
|
[5] |
SHEN Yanjie, WU Yiqing.
Management of adverse events during clinical trials
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 982-986.
|
[6] |
ZANG Tianying, LIU Bingyang, TANG Xiaojun.
Differentiation of vancomycin induced anaphylactoid and anaphylactic reactions
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 1078-1080.
|
[7] |
ZI Wenrui, YANG Qiuyue, SU Jun, XIE Jiang'an.
The research development of inoculation safety associated with licensed HPV vaccines in China
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(3): 311-316.
|
[8] |
YE Pei, ZHANG Hewei, LYU Qiang, YE Xiaofei, XU Jinfang, GUO Xiaojing.
Safety of sugammadex for reversal of neuromuscular block based on FAERS database
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(3): 321-325.
|
[9] |
HAO Xiaohui, ZHANG Ping, WU Lulu, WANG Lihua.
Mining and analysis of ixazomib citrate capsules safety signals based on FAERS database
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(12): 1427-1431.
|
[10] |
ZHAO Huanhuan, SONG Jiawei, LIU Jinguang, HUANG Minghui.
One case of nephrotic syndrome caused by rabies vaccine in a 5-year-old child
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(11): 1303-1305.
|
[11] |
WU Yunxiao, YU Yuelin, WANG Shengfeng, SUN Feng, MENG Ruogu, ZHAN Siyan.
Suitability assessment of real-world data in active post-marketing surveillance of vaccine safety
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(10): 1081-1089.
|
[12] |
WANG Tao, ZHENG Mingjie, LIU Hongliang, WANG Qing, SHEN Chuanyong.
Current applications of artificial intelligence in pharmacovigilance in the USA and implications
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(10): 1129-1133.
|
[13] |
YU Min, LI Xin.
Immunerelated adverse events and risk factors of carrelizumab in 528 cases of cancer patients
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(10): 1134-1140.
|
[14] |
YANG Qiuyue, SU Jun, ZHANG Xue, XIE Jiangan.
Adverse events associated with the three US licensed COVID-19 vaccines based on VAERS database
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(10): 1141-1147.
|
[15] |
ZHOU Pengbo, ZHOU Xiaobing, HUANG Ying, GENG Xingchao.
Research progress in oncolytic drugs
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(1): 7-11.
|